VANCOUVER, BC, April 8, 2021 /CNW/ - Rakovina
Therapeutics Inc. (the "Company") (TSXV: RKV)
today announced that the Company has been granted patents entitled
"Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase" by the
European and Canadian Patent Offices.
The granted patent claims cover the composition of matter and
uses of drug candidates from Rakovina Therapeutics' kt-2000 series,
one of three novel series of DNA-damage response inhibitors being
researched by the Company as potential targeted cancer therapies
under a collaborative research agreement with the University of
British Columbia.
"With our focus on the rapid progress of our research programs,
we are pleased to receive these patent allowances in Europe and Canada," said Prof. Mads Daugaard, Rakovina Therapeutics' president
and chief scientific officer. "These patents further
establish our strong global intellectual property protection and
provide patent claims in Canada
and the European Union into 2032, supporting our commitment to
optimize drug candidates from the kt-2000 series for advancement
toward the initiation of human clinical trials."
About Rakovina's kt-2000 Series Drug Candidates
Rakovina Therapeutics' kt-2000 series drug candidates are oral
targeted small molecule inhibitors of poly (ADP-ribose) polymerase
(PARP). Established data demonstrate that lead candidates
from Rakovina Therapeutics' kt-2000 series exhibit potency
comparable to FDA-approved PARP-inhibitors and potent anti-cancer
activity in preclinical animal models. kt-2000 series lead
candidates are being optimized around several differentiating
factors and potential competitive advantages.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. was established in 2020 to develop
new cancer treatments based on novel DNA-damage response
technologies. The Company has established a pipeline of
DNA-damage response inhibitors with the goal of advancing one or
more drug candidates into human clinical trials and obtaining
marketing approval for new cancer therapeutics from Health Canada,
the United States Food and Drug Administration and similar
international regulatory agencies. Further information may be
found at www.rakovinatherapeutics.com.
Additional Information
The TSXV has neither approved nor disapproved the content of
this press release. Neither the TSXV nor its Regulation Services
Provider (as that term is defined in policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this
release.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding
the Company and its respective business, which may include, but is
not limited to, statements with respect to the proposed business
plan of the Company and other statements. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events, or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of the
Company. The forward-looking events and circumstances discussed in
this release may not occur by certain specified dates or at all and
could differ materially as a result of known and unknown risk
factors and uncertainties affecting the Company, including risks
regarding the medical device industry, economic factors, regulatory
factors, the equity markets generally and risks associated with
growth and competition. Although the Company has
attempted to identify important factors that could cause actual
actions, events, or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events, or results to differ from those
anticipated, estimated or intended. No forward-looking statement
can be guaranteed. Except as required by applicable securities
laws, forward-looking statements speak only as of the date on which
they are made and the Company undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result
of new information, future events, or otherwise. The
reader is referred to the Company's most recent filings on SEDAR
for a more complete discussion of all applicable risk factors and
their potential effects, copies of which may be accessed through
the Company's profile page at www.sedar.com.
SOURCE Rakovina Therapeutics Inc.